Biohacker Protocol (experimental) Dose: 0.05 0.1 mg (= 24 clicks) Duration: 10 16 weeks Frequency: 1 2 per day Cycle Interval: Continuous with periodic 2-week washouts Goal / Description: Microdose continuous model for studying sustained ghrelin receptor activation

Key Points Native human GLP-1 normalizes hyperglycaemia in patients with type 2 diabetes mellitus, but the short in vivo half-life of this hormone limits its therapeutic application A number of synthetic GLP-1 receptor agonists, with half-lives between 23 h and several days, have been developed for the long-term treatment of type 2 diabetes mellitus Short-acting GLP-1 receptor agonists (such as exenatide and lixisenatide) predominantly lower postprandial glucose levels and insulin concentrations via retardation of gastric emptying Long-acting GLP-1 receptor agonists (such as albiglutide, dulaglutide, exenatide long-acting release and liraglutide) predominantly lower blood glucose levels through stimulation of insulin secretion and reduction of glucagon levels Adverse effects of GLP-1 receptor agonists include nausea, vomiting and diarrhoea, injection-site reactions, antibody formation and increased heart rate This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 189,00 per year only 15,75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

For a peer-reviewed look at why the peptide attracts so much interest, this review of BPC-157s cytoprotective and healing effects across multiple tissue systems published in Current Pharmaceutical Design summarizes the preclinical evidence base behind the recovery claims
Many people turn to glutathione IV vials for skin whitening, but Relumins has developed an advanced formula that ensures rapid absorption when taken orally
Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Womens Heart and Health Study and Meta-Analysis
Supporting GLP-1 Naturally Through the Microbiome GLP-1 is often discussed as a hormone that can be increased through medication, but emerging research shows that it is also deeply influenced by the gut microbiome